Core Viewpoint - The approval of "Rotigotine Transdermal Patch" by the National Medical Products Administration marks a significant milestone for the company, as it is the first domestically approved generic version for treating Parkinson's disease in China [1] Group 1: Product Approval - The "Rotigotine Transdermal Patch" is the world's first transdermal patch for the treatment of Parkinson's disease, initially approved in the EU in 2006 and imported to China in 2018 [1] - The product is indicated for the treatment of early-stage idiopathic Parkinson's disease symptoms and can be used as a monotherapy or in combination with Levodopa throughout the disease stages [1] Group 2: Market Potential - The global sales forecast for the "Rotigotine Transdermal Patch" is projected to reach $330 million in 2024 [1] - The approval enhances the company's competitive position in the central nervous system (CNS) therapeutic area, where it already has multiple products approved and on the market [1]